Production resumes at Evonik methionine manufacturing plants in Antwerp, Belgium
- Temporary outage of hydrocyanic acid supply for methionine production in Antwerp, Belgium resolved
- Force Majeure ends
Evonik has stated that the force majeure announced on Tuesday 12 November has now ended.
An issue with the hydrocyanic acid (HCN) supply caused a temporary shutdown of its methionine manufacturing facilities in Antwerp.
Dr. Emmanuel Auer, Head of Animal Nutrition Business Line at Evonik said: “We are pleased that we could solve the issue and resume MetAMINO® production.
“We would like to thank our customers for the patience and support shown whilst we resolved the situation.”
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world. In fiscal 2018, the enterprise with more than 32,000 employees generated sales of €13.3 billion and an operating profit (adjusted EBITDA) of €2.15 billion from continuing operations.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,200 employees, and generated sales of around €4.6 billion in 2018.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.